• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Elixir Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010 Product Image

Elixir Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

  • ID: 1446283
  • November 2010
  • 40 pages
  • GlobalData

Elixir Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Elixir Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Elixir Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Elixir Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Elixir Pharmaceuticals, Inc. Snapshot
Elixir Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Elixir Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Elixir Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Elixir Pharmaceuticals, Inc. – Pipeline Products Glance
Elixir Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Elixir Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Elixir Pharmaceuticals, Inc. – Drug Profiles
Glinsuna
Product Description
Mechanism of Action
R&D Progress
Metgluna
Product Description
Mechanism of Action
R&D Progress
EX-1314
Product Description
Mechanism of Action
R&D Progress
Ghrelin Antagonist
Product Description
Mechanism of Action
R&D Progress
SIRT2 Inhibitor
Product Description
Mechanism of Action
R&D Progress
Elixir Pharmaceuticals, Inc. – Pipeline Analysis
Elixir Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Elixir Pharmaceuticals, Inc. Pipeline Products By Target
Elixir Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Elixir Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Elixir Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Jan 07, 2010: Elixir Announces Initiation Of Phase 1 Clinical Trial Of EX-527 For The Treatment Of Huntington’s Disease
May 19, 2009: Elixir Pharmaceuticals Signs Option Agreement With Novartis
Nov 19, 2008: Elixir Pharmaceuticals Announces Phase III Trial Of Metformin-Mitiglinide Combination Therapy With Significant Reductions In HbA1c (Blood Glucose) Levels
Jun 18, 2008: Elixir Pharmaceuticals Announces Ghrelin Agonist Data Presentation at the Endocrine Society Annual Meeting First Presentation of Data Demonstrating Increases in Gastrointestinal Motility by an Orally Active Ghrelin Agonist
Jun 18, 2008: Elixir Pharmaceuticals Announces Ghrelin Agonist Data Presentation at the Endocrine Society Annual Meeting First Presentation of Data Demonstrating Increases in Gastrointestinal Motility by an Orally Active Ghrelin Agonist
Jun 18, 2008: Elixir Pharmaceuticals Announces Ghrelin Agonist Data Presentation at the Endocrine Society Annual Meeting First Presentation of Data Demonstrating Increases in Gastrointestinal Motility by an Orally Active Ghrelin Agonist
Apr 28, 2008: Elixir Pharmaceuticals Announces Issuance Of SIRT Patent Covering Development Of New Therapies Based On Breakthrough Science
Apr 28, 2008: Elixir Pharmaceuticals Announces Issuance Of SIRT Patent Covering Development Of New Therapies Based On Breakthrough Science
Mar 25, 2008: Elixir Announces Completion Of Enrollment In Pivotal Phase III Clinical Trial For New Diabetes Drug
Nov 30, 2006: Elixir Pharmaceuticals Presents Ghrelin Antagonist Program at European Conference on Aging
Financial Deals Landscape
Elixir Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
Elixir Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
Elixir Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
Elixir Pharmaceuticals, Inc. Detailed Deal Summary
Venture Financing
Elixir Pharmaceuticals Secures $12 Million In Venture Financing
Elixir Pharmaceuticals Secures $31 Million In Series C Financing
Licensing Agreements
Elixir Pharmaceuticals Enters Into Licensing Agreement With Boston University
Kissei Pharmaceutical Enters Into Licensing Agreement With Elixir Pharmaceuticals
Elixir Pharmaceuticals Extends Licensing Agreement With The University Of California Regents
Elixir Pharmaceuticals Enters Into License Agreement With Bristol-Myers Squibb
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS